HS

Heart Test Laboratories IncNASDAQ HSCS Stock Report

Last reporting period 30 Apr, 2024

Updated 26 Nov, 2024

Last price

Market cap $B

0.004

Micro

Exchange

XNAS - Nasdaq

HSCS Stock Analysis

HS

Uncovered

Heart Test Laboratories Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-31/100

Low score

Market cap $B

0.004

Dividend yield

Shares outstanding

8.35 B

Heart Test Laboratories, Inc. is a medical technology company focused on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. The company is headquartered in Southlake, Texas and currently employs 12 full-time employees. The company went IPO on 2022-06-15. The Company’s product candidate, the MyoVista wavECG, or the MyoVista, is designed to provide diagnostic information related to cardiac dysfunction. The MyoVista is a 12-lead resting ECG device that features its algorithm developed to detect cardiac dysfunction in the diastolic phase, specifically slower than normal left ventricular relaxation rates. The MyoVista uses electrical information from the heart captured during a standard resting 12-lead ECG test as inputs to an artificial intelligence-based algorithm. The MyoVista detects whether a patient is negative or positive for abnormally slow left ventricular diastolic relaxation rates.

View Section: Eyestock Rating